RECENT NEWS
Forbes  Oct 29  Comment 
Glenn Watt discusses how data security has changed in the cloud era, as well as its role in transforming clinical trials and the patient experience.
Benzinga  Oct 27  Comment 
Novavax, Inc. (NASDAQ: NVAX) will launch a Phase 1 clinical trial of an Ebola vaccine candidate in December, the company said at a conference Sunday in Philadelphia. Novavax gained 5 percent in Monday's session, trading recently at $5.36 per...
Forbes  Oct 25  Comment 
French doctor turned entrepreneur Pierre-Henri Benhamou led his team to an IPO on the Nasdaq this week as part of his mission to expand his biotech startup on US soil. CEO Benhamou is developing Viaskin, a small patch peanut allergy sufferers can...
Benzinga  Oct 23  Comment 
Co announced positive top-line results from clinical trials in treatment and prevention of Alzheimer's disease as part of the collaboration with Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. The two Phase 1...
Benzinga  Oct 22  Comment 
Intellipharmaceutics International Inc. (Nasdaq: IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided...
Benzinga  Oct 20  Comment 
Cytokinetics, Incorporated (Nasdaq: CYTK) provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program.  The company announced that it has completed its review...
newratings.com  Oct 20  Comment 
BASEL (dpa-AFX) - MorphoSys AG (MPSYY.PK) announced it has received a milestone payment from Novartis in connection with the initiation of a Phase 1 clinical trial of a HuCAL antibody in the field of diabetic eye diseases. The official start of...
SeekingAlpha  Oct 18  Comment 
By Pharma Doc: Background: The Ebola virus is a single-stranded, negative-sense RNA virus of the family Filoviridae. The Ebola virus is transmitted by exposure of mucosal surfaces to infected body fluids or through parenteral inoculation....
GenEng News  Oct 17  Comment 
Profectus BioSciences yesterday was awarded a one-year, about $5.8 million contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) toward developing an Ebola vaccine. Profectus plans to manufacture vaccine for use...




 
TOP CONTRIBUTORS

Clinical trials are the process by which a new drug's safety and effectiveness are tested as part of the FDA approval process. When a company discovers and develops a new drug, they must first run extensive pre-clinical trials prior to testing the drug candidate on people. This pre-clinical development process serves to determine a drug's safety, the best starting dose for human clinical trials, and the interaction between the body and the drug. Once pharmaceutical companies have enough information about the drug, they can apply for approval to run clinical trials on humans.

Companies impacted by clinical trials

Error creating thumbnail
Development pipeline for major pharmaceutical companies

Pharmaceutical companies

Clinical trials can only come after extensive pre-clinical testing and development, which can be costly. Additionally, clinical trials themselves are very expensive to conduct. If a company's drug reaches a late-stage clinical trial and fails, the money spent up until that point will be lost. Any pharmaceutical company involved in the development of new drugs can be significantly impacted by the results of clinical trials, either positively or negatively.

Major pharmaceutical companies include:

As shown in the graph, these companies have anywhere from 20 to 140 new products in various stages of development. In general, Phase II is the most common place for drug candidates to fail. As such, companies with a higher percentage of products that either are in Phase III clinical trials or for which they've already filed a new drug application (NDA) are at somewhat lower risk of failing a clinical trial.

Manufacturers of medical equipment, such as Advanced Medical Optics, are impacted by clinical trials as well.

Clinical testing process

    • After a dClinical trials are generally divided into four phases, though the FDA did establish a new Phase 0 designation for initial human trials. Including this recent addition, the five phases of clinical trials are:
  • Phase 0
    • This phase is aimed at determining whether a drug will behave in humans in the way that pre-clinical testing indicated. A small dosage, below the amount expected to be used therapeutically, is given to a small number of subjects to determine if the drug will act on the part of the body on which it was designed to act. For example, a drug designed to lower cholesterol would be tested to see if it acts on particular parts of the body (blood vessels, the heart, etc.) and to see if that interaction is in line with expectations. This can prevent further, unnecessary testing in the event of a drug's not acting as predicted.
  • Phase I
    • This is the first major stage in the clinical testing process. The drug is administered to a small group of subjects in an inpatient clinic, where the subjects can be monitored constantly. The main purpose of Phase I trials are to determine several things about a drug candidate, including its toxicity, side effects, interaction with the body, and proper dosage levels. There are a few different types of Phase I trials, but the basic premise is that the subjects receive an increasing dosage of the drug while being monitored for side effects. Other factors are also tested, such as the impact of food consumption on the drug's effectiveness,
  • Phase IIrug's initial safety has been established, Phase II trials are commenced. In this stage, the drug is administered to a larger group of people, allowing further study of a candidate's effectiveness. Phase II trials also continue the safety assessments started in Phase I. The main purpose, however, is to determine a drug's efficacy, or whether its effect on the body is significant enough to warrant further testing.
  • Phase III
    • Phase III trials are generally the last stop on a drug's way from the lab to the pharmacy. These trials involve large subject groups and are designed to be the final assessment of a drug's efficacy and side effects. Phase III trials go one step further by comparing the drug candidate to the current standard treatment for a particular condition. If a drug is effective but shows no significant benefits over a treatment already in use, it can still be approved for production, though sales might not be as high as its developer had hoped. In the news, a drug that is proven to be safe and effective but that doesn't offer any advantages over the current "gold standard" treatment is often said to have "failed" the Phase III trials. While this something of a misnomer, it reflects the importance for pharmaceutical companies to develop innovative drugs that improve on existing treatment options.
  • Phase IV
    • Phase IV clinical trials occur after the approval and release of a new drug. These trials, which are sometimes not required, are used to further understand a drug's mechanism of action. For example, Phase IV trials often test the drug's interactions with other drugs and its effectiveness in certain populations that were not present in previous clinical trials. Additionally, drugs in this phase are monitored for long-term side effects that clinical trials were unable to detect. This can be important, since the relatively short duration of the clinical testing process doesn't allow for the observance of a drug's long-term impact on subjects. Vioxx, the blockbuster osteoarthritis drug made by Merck (MRK), is a well-known example of a drug recalled as a result of continual monitoring for safety.
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki